Dr. Moore joined Zymeworks in July 2022 and serves as our Chief Scientific Officer. Dr. Moore has more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics from April 2008 to July 2022, leading a team of approximately 50 researchers engaged in the discovery, preclinical validation and clinical development of antibody-based therapeutics, including bispecific antibodies and antibody drug conjugates. Among the portfolio supported by Dr. Moore were FDA-approved Margenza (margetuximab-cmkb) for treatment of HER2+ breast cancer, Zynyz (retifanlimab-dlwr) for treatment of Merkel cell carcinoma and Tzield (teplizumab-mzwv) to delay onset of type I diabetes. Prior to joining MacroGenics, Dr. Moore was Director of Cell Biology at Celera from May 2005 to April 2008, where he oversaw research leveraging proteomic-based discoveries to validate novel cancer targets suitable for antibody-based therapeutics. Dr. Moore began his industrial career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents. Dr. Moore holds a Ph.D. in Molecular Genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde.

Ms. Patterson joined Zymeworks in September 2024 and serves as our Executive Vice President, Chief Business Officer and Chief Financial Officer. Ms. Patterson served as Chief Financial Officer and Business Officer of Tenaya Therapeutics, Inc. from June 2021 until August 2024. Prior to joining Tenaya Therapeutics, Inc., Ms. Patterson joined Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company, in June 2016 as the Chief Financial Officer and also served as Chief Executive Officer from May 2018 to June 2020, director from October 2018 to June 2020, and President from July 2020 to June 2021. Ms. Patterson has held various senior positions at Diadexus, Inc., Transcept Pharmaceuticals, Inc., NetApp, Inc., Exelixis, Inc., Novartis AG, Chiron (acquired by Novartis AG), and KPMG. Ms. Patterson currently serves on the board of directors and as the chair of the audit committee of Nkarta, Inc., a publicly traded biotechnology company. She previously served as a member of the board of directors of Eliem Therapeutics, Inc. from March 2021 to December 2024 and Adverum Biotechnologies, Inc. from October 2018 to June 2020, both publicly traded biotechnology companies, and as a member of the board of directors of Oxford Biomedica (UK) Limited from March 2023 to December 2024, a publicly traded contract development and manufacturing organization focuses on cell and gene therapy. Ms. Patterson has served on the board of directors of Kalaris Therapeutics, Inc. and as Chair of the board’s audit committee since April 2025. Ms. Patterson holds a B.S. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).

Dr. Smith joined Zymeworks in January 2023 as Senior Vice President, Early Stage Development and was promoted to Executive Vice President and Chief Medical Officer in January 2024. He is based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry. Previously, Dr. Smith served as the Managing Director of Alder Biopharmaceuticals Inc. in Dublin, Ireland from March 2017 to October 2019, and as Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc. in Seattle, USA from 2012 to March 2017. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti-IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceuticals Inc. (founded 2004). Dr. Smith received his M.B. B.S. and M.D. from the University of London, UK and is a Fellow of the Royal College of Physicians in London.

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Dr. Fann joins Zymeworks with more than 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Vice President, Finance & Strategy. Ms. Desai brings more than 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her M.B.A. with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Vice President, Business & Commercial Development since January 2024. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an M.B.A. from the University of Washington.

Dr. Foulkes joined Zymeworks in January 2024, bringing over 25 years of experience in the biotechnology, biopharma and medical device industries. Prior to joining Zymeworks, Dr. Foulkes was Chief Operating Officer of Arecor, a UK AIM-listed, clinical-stage biopharmaceutical company. Joining at the point of IPO, she implemented organizational and operational changes to position the company for future growth. Dr. Foulkes has held senior commercial roles covering corporate and business development, marketing and clinical portfolio management, with a therapeutic focus on immunology, inflammation, oncology and rare diseases. She has worked for organizations including Liminal Biosciences (previously known as Prometic Life Sciences), Acambis, and Cangene Corporation, and she was part of the start-up team for the medical device company, Nexan Ltd. Dr. Foulkes started her commercial career in management consultancy with McKinsey & Company and during her career she has also worked as a freelance consultant providing business development, strategy and market analysis support within the biotechnology industry, with a focus on oncology and immunology companies. Dr. Foulkes holds a Ph.D. in Leukaemia Research and a B.Sc in Immunology, awarded by the University of Glasgow.

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Vice President, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Vice President, Human Resources & DEI. Ms. O’Connor brings more than 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Ms. Schaeffler joined Zymeworks in January 2024, bringing over 27 years of experience in the biotechnology and biopharma industries. Prior to joining Zymeworks, Ms. Schaeffler was Vice President of Clinical Operations at Syndax Pharmaceuticals, a clinical-stage oncology company developing first-in-class therapies for acute leukemias and chronic graft-versus host disease. Ms. Schaeffler has held senior roles covering clinical development and operations, leading departments and project development teams through all phases of clinical trials, culminating in regulatory filings and drug approvals. She has worked for organisations including Lundbeck, Alder Biopharmaceuticals (acquired by Lundeck), Poniard Pharmaceuticals (formerly NeoRx, Corporation), Pathogenesis and Chiron (acquired by Novartis) and PATH. Ms. Schaeffler holds an M.B.A. and a bachelor’s degree in Bacteriology from the University of California.